Record Nr. UNINA9910143578003321 Pharmacometrics: the science of quantitative pharmacology / / edited **Titolo** by Ene I. Ette, Anoixis Corporation, Paul J. Williams, University of the Pacific and Anoixis Corporation Hoboken, New Jersey: ,: Wiley-Interscience, , [2007] Pubbl/distr/stampa ©2007 **ISBN** 1-118-67951-2 1-280-82698-3 9786610826988 0-470-08797-8 0-470-08796-X Descrizione fisica 1 online resource (1227 p.) Classificazione 44.38 Disciplina 615.1 615/.1 Soggetti Pharmacology **Pharmacokinetics** Lingua di pubblicazione Inglese **Formato** Materiale a stampa Livello bibliografico Monografia Description based upon print version of record. Note generali Nota di bibliografia Includes bibliographical references and index. Nota di contenuto PHARMACOMETRICS: CONTENTS: CONTRIBUTORS: PREFACE: ACKNOWLEDGMENTS: 1. Pharmacometrics: Impacting Drug Development and Pharmacotherapy; PART I GENERAL PRINCIPLES; 2. General Principles of Programming: Computer and Statistical; 3. Validation of Software for Pharmacometric Analysis: 4. Linear. Generalized Linear, and Nonlinear Mixed Effects Models; 5. Bayesian Hierarchical Modeling with Markov Chain Monte Carlo Methods; 6. Estimating the Dynamics of Drug Regimen Compliance; 7. Graphical Displays for Modeling Population Data; 8. The Epistemology of Pharmacometrics; 9. Data Imputation PART II POPULATION PHARMACOKINETIC BASIS OF PHARMACOMETRICS10. Population Pharmacokinetic Estimation Methods; 11. Timing and Efficiency in Population Pharmacokinetic/Pharmacodynamic Data Analysis Projects; 12. Designing Population Pharmacokinetic Studies for Efficient Parameter

Estimation; 13. Population Models for Drug Absorption and Enterohepatic Recycling: 14. Pharmacometric Knowledge Discovery from Clinical Trial Data Sets: 15. Resampling Techniques and Their Application to Pharmacometrics; 16. Population Modeling Approach in Bioequivalence Assessment

PART III PHARMACOKINETICS / PHARMACODYNAMICS RELATIONSHIP: BIOMARKERS AND PHARMACOGENOMICS, PK/PD MODELS FOR CONTINUOUS DATA, AND PK/PD MODELS FOR OUTCOMES DATA17.

Biomarkers in Drug Development and Pharmacometric Modeling; 18.

Analysis of Gene Expression Data; 19. Pharmacogenomics and Pharmacokinetic/Pharmacodynamic Modeling; 20. Empirical

Pharmacokinetic/Pharmacodynamic Models: 21. Developing Models of Disease Progression: 22. Mechanistic

Pharmacokinetic/Pharmacodynamic Models I; 23. Mechanistic Pharmacokinetic/Pharmacodynamic Models II; 24. PK/PD Analysis of Binary (Logistic) Outcome Data

25. Population Pharmacokinetic/Pharmacodynamic Modeling of Ordered Categorical Longitudinal Data26. Transition Models in Pharmacodynamics: 27. Mixed Effects Modeling Analysis of Count Data: 28. Mixture Modeling with NONMEM V; PART IV CLINICAL TRIAL DESIGNS; 29. Designs for First-Time-in-Human Studies in Nononcology Indications; 30. Design of Phase 1 Studies in Oncology; 31. Design and Analysis of Clinical Exposure: Response Trials: PART V PHARMACOMETRIC KNOWLEDGE CREATION: 32.

Pharmacometric/Pharmacodynamic Knowledge Creation: Toward Characterizing an Unexplored Region of the Response Surface 33. Clinical Trial Simulation: Theory34. Modeling and Simulation: Planning and Execution: 35. Clinical Trial Simulation: Efficacy Trials: PART VI PHARMACOMETRIC SERVICE AND COMMUNICATION; 36. Engineering a Pharmacometrics Enterprise; 37. Communicating Pharmacometric Analysis Outcome; PART VII SPECIFIC APPLICATION EXAMPLES; 38. Pharmacometrics Applications in Population Exposure-Response Data for New Drug Development and Evaluation; 39. Pharmacometrics in Pharmacotherapy and Drug Development: Pediatric Application

40. Pharmacometric Methods for Assessing Drug-Induced QT and QTc Prolongations for Non-antiarrhythmic Drugs

Sommario/riassunto

Pharmacometrics is the science of interpreting and describing pharmacology in a quantitative fashion. The pharmaceutical industry is integrating pharmacometrics into its drug development program, but there is a lack of and need for experienced pharmacometricians since fewer and fewer academic programs exist to train them. Pharmacometrics: The Science of Quantitative Pharmacology lays out the science of pharmacometrics and its application to drug development, evaluation, and patient pharmacotherapy, providing a comprehensive set of tools for the training and development of pharmac

2. Record Nr. UNISA996385494203316

Autore Culpeper Thomas, Sir, <1626-1697.>

Titolo A discourse, shewing the many advantages which will accrue to this

kingdom by the abatement of usury [[electronic resource]]: together with the absolute necessity of reducing interest of money to the lowest rate it bears in other countreys, that, at least, we may trade with our neighbours upon equal termes. Humbly presented to the High Court of

Parliament now sitting. By Sir Tho. Culpeper jun. Kt

Pubbl/distr/stampa London, : printed by Tho. Leach, for Christopher Wilkinson, at the

Black-Boy over against St. Dunstans Church in Fleetstreet, 1668

Descrizione fisica [12], 34 p

Soggetti Usury - England

Interest - England

Lingua di pubblicazione Inglese

Formato Materiale a stampa

Livello bibliografico Monografia

Note generali Reproduction of the original in the Cambridge University Library.

Sommario/riassunto eebo-0021